| Style | Citing Format |
|---|---|
| MLA | Safari M, et al.. "The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis." Journal of Nephropharmacology, vol. 14, no. 2, 2025, pp. -. |
| APA | Safari M, Kareem AK, Rigi K, Abbasi A, Mokhtarinia B, Pourpashang P, Ahmadipour E, Heydarisadegh B, Aali H (2025). The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis. Journal of Nephropharmacology, 14(2), -. |
| Chicago | Safari M, Kareem AK, Rigi K, Abbasi A, Mokhtarinia B, Pourpashang P, Ahmadipour E, Heydarisadegh B, Aali H. "The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis." Journal of Nephropharmacology 14, no. 2 (2025): -. |
| Harvard | Safari M et al. (2025) 'The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis', Journal of Nephropharmacology, 14(2), pp. -. |
| Vancouver | Safari M, Kareem AK, Rigi K, Abbasi A, Mokhtarinia B, Pourpashang P, et al.. The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis. Journal of Nephropharmacology. 2025;14(2):-. |
| BibTex | @article{ author = {Safari M and Kareem AK and Rigi K and Abbasi A and Mokhtarinia B and Pourpashang P and Ahmadipour E and Heydarisadegh B and Aali H}, title = {The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis}, journal = {Journal of Nephropharmacology}, volume = {14}, number = {2}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Safari M AU - Kareem AK AU - Rigi K AU - Abbasi A AU - Mokhtarinia B AU - Pourpashang P AU - Ahmadipour E AU - Heydarisadegh B AU - Aali H TI - The Association Between Triglyceride-Glucose Index and Contrast-Induced Nephropathy; a Systematic Review and Meta-Analysis JO - Journal of Nephropharmacology VL - 14 IS - 2 SP - EP - PY - 2025 ER - |